Connor, Clark & Lunn Investment Management Ltd. Axsome Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.8 Billion
Q1 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$57.42 - $83.61 $823,345 - $1.2 Million	14,339 New	14,339 $1.14 Million
Q2 2022 Aug 05, 2022	SELL	$21.74 - $46.75 $199,899 - $429,866	-9,195 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$23.7 - $41.39 $217,921 - $380,581	9,195 New	9,195 $381,000

Others Institutions Holding AXSM

# of Institutions

290

Shares Held

37.1M

Call Options Held

401K

Put Options Held

464K

Rtw Investments, LP New York, NY

4.49M
Shares

$355 Million
5.75% of portfolio
Vanguard Group Inc Valley Forge, PA

3.74M
Shares

$295 Million
0.01% of portfolio
Black Rock Inc. New York, NY

3.2M
Shares

$252 Million
0.01% of portfolio
Fairmount Funds Management LLC Philadelphia, PA

2.36M
Shares

$186 Million
30.01% of portfolio
Deep Track Capital, LP Greenwich, CT

1.3M
Shares

$103 Million
3.44% of portfolio

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account